Reluscovtogene ralaplasmid

雷拉瑞斯科基

Report date: 2022/10/14 20:00:43

Base Information

Drug NameReluscovtogene ralaplasmid
Drug Alias NameINO-4800INO4800PGX-9501
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus InfectionsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInovio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesInovio Pharmaceuticals IncSuzhou Aidi Weixin Biotechnology CompanyInternational Vaccine Institute +[4] 
Inactive CompaniesAdvaccine(Suzhou) Biopharmaceuticals Co Ltd
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsHepatitis B, Chronic

Other Information

ATC CodeN/A
Related LinksN/A